{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:57:19Z","timestamp":1793681839129,"version":"4.5.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The beneficial cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors irrespective of the presence of diabetes mellitus are nowadays well established and they already constitute a significant pillar for the management of heart failure, irrespective of the ejection fraction. The exact underlying mechanisms accountable for these effects, however, remain largely unknown. The direct effect on endothelial function and microcirculation is one of the most well studied. The broad range of studies presented in this review aims to link all available data from the bench to bedside and highlight the existing gaps as well as the future directions in the investigations concerning the effects of SGLT2 inhibitors on the endothelium and the microcirculation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>An extensive search has been conducted using the MEDLINE\/PubMed database in order to identify the relevant studies. Preclinical data suggest that SGLT2 inhibitors directly affect endothelial function independently of glucose and specifically via several interplaying molecular pathways, resulting in improved vasodilation, increased NO production, enhanced mitochondrial homeostasis, endothelial cell viability, and angiogenesis as well as attenuation of oxidative stress and inflammation. Clinical data systematically confirm this beneficial effect on the endothelium, whereas the evidence concerning the effect on the microcirculation is conflicting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preclinical and clinical studies indicate that SGLT2 inhibitors attenuate endothelial and microvascular dysfunction via a combination of mechanisms, which play a role in their beneficial cardiovascular effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad053","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:10:45Z","timestamp":1690391445000},"page":"741-757","source":"Crossref","is-referenced-by-count":47,"title":["The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-8905","authenticated-orcid":false,"given":"Kyriakos","family":"Dimitriadis","sequence":"first","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Adamopoulou","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-9473","authenticated-orcid":false,"given":"Nikolaos","family":"Pyrpyris","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Sakalidis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Leontsinis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Manta","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Mantzouranis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Beneki","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Soulaidopoulos","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Konstantinidis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Fragkoulis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Aggeli","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital , 115 27, Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2023121405224366300_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob\u2212\/\u2212 mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"Mcmurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121405224366300_bib8","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1093\/ehjcvp\/pvac029","article-title":"Updated ACC\/AHA\/HFSA 2022 guidelines on heart failure: what's new? From epidemiology to clinical management","volume":"8","author":"Santulli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023121405224366300_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11357-022-00563-x","article-title":"SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice","volume":"44","author":"Soares","year":"2022","journal-title":"Geroscience"},{"key":"2023121405224366300_bib10","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.3390\/jcm9092880","article-title":"Coronary microvascular dysfunction","volume":"9","author":"Vancheri","year":"2020","journal-title":"J Clin Med"},{"key":"2023121405224366300_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-018-0797-6","article-title":"Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus","volume":"17","author":"Lunder","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib12","doi-asserted-by":"crossref","first-page":"18384","DOI":"10.1038\/s41598-021-97787-2","article-title":"Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload","volume":"11","author":"Nakao","year":"2021","journal-title":"Sci Rep"},{"key":"2023121405224366300_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023121405224366300_bib14","doi-asserted-by":"crossref","first-page":"102417","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"2023121405224366300_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023121405224366300_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"key":"2023121405224366300_bib18","doi-asserted-by":"crossref","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"2023121405224366300_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib20","doi-asserted-by":"crossref","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol"},{"key":"2023121405224366300_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"2023121405224366300_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated Human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2023121405224366300_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-022-01532-6","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion injury through improving mitochondrial homeostasis","volume":"21","author":"Zou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib24","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.7150\/thno.75121","article-title":"SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"2023121405224366300_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by Empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2023121405224366300_bib26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","article-title":"Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction","volume":"99","author":"Juni","year":"2021","journal-title":"Kidney Int"},{"key":"2023121405224366300_bib27","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023121405224366300_bib28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 Inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"key":"2023121405224366300_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","article-title":"Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress","volume":"109","author":"El-Daly","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"2023121405224366300_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbrc.2022.05.022","article-title":"Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1\/PGC-1\u03b1 pathway in obese mice","volume":"615","author":"He","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"2023121405224366300_bib31","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 Inhibition via Empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"2023121405224366300_bib32","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1111\/bph.15850","article-title":"Amelioration of endothelial dysfunction by sodium glucose cotransporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection","volume":"179","author":"Li","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2023121405224366300_bib33","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms22116044","article-title":"Sodium glucose Co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023121405224366300_bib34","doi-asserted-by":"crossref","first-page":"107095","DOI":"10.1016\/j.vph.2022.107095","article-title":"Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2","volume":"146","author":"Bruckert","year":"2022","journal-title":"Vasc Pharmacol"},{"key":"2023121405224366300_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic Empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"2023121405224366300_bib36","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol Res"},{"key":"2023121405224366300_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2023121405224366300_bib38","doi-asserted-by":"crossref","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2023121405224366300_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"2023121405224366300_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","article-title":"Empagliflozin restores the integrity of the endothelial glycocalyx in vitro","volume":"459","author":"Cooper","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"2023121405224366300_bib41","doi-asserted-by":"crossref","first-page":"12681","DOI":"10.1038\/s41598-022-16763-6","article-title":"Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption","volume":"12","author":"Campeau","year":"2022","journal-title":"Sci Rep"},{"key":"2023121405224366300_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jacc.2014.11.025","article-title":"The pathophysiological role of interstitial sodium in heart failure","volume":"65","author":"Nijst","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023121405224366300_bib43","doi-asserted-by":"crossref","first-page":"1479164119883540","DOI":"10.1177\/1479164119883540","article-title":"Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: results from an exploratory study","volume":"17","author":"Irace","year":"2020","journal-title":"Diab Vasc Dis Res"},{"key":"2023121405224366300_bib44","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.2337\/dc19-1177","article-title":"Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial","volume":"42","author":"Tanaka","year":"2019","journal-title":"Diabetes Care"},{"key":"2023121405224366300_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","article-title":"Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial","volume":"20","author":"Sposito","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib46","first-page":"bvz017","article-title":"Effects of Dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED)","volume-title":"J Endocr Soc","author":"Zainordin","year":"2019"},{"key":"2023121405224366300_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib49","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1210\/jc.2019-00706","article-title":"The effects of Dapagliflozin on systemic and renal vascular function display an epigenetic signature","volume":"104","author":"Solini","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2023121405224366300_bib50","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor Dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern Med"},{"key":"2023121405224366300_bib51","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/ehf2.13553","article-title":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial","volume":"8","author":"Ilyas","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2023121405224366300_bib52","doi-asserted-by":"crossref","first-page":"e020418","DOI":"10.1161\/JAHA.120.020418","article-title":"Effects of empagliflozin on myocardial flow reserve in patients with type 2 diabetes mellitus: the SIMPLE trial","volume":"10","author":"J\u00fcrgens","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023121405224366300_bib53","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2337\/db20-0921","article-title":"SGLT2 Inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 Diabetes: a randomized double-blind, placebo-controlled crossover trial","volume":"70","author":"Lauritsen","year":"2021","journal-title":"Diabetes"},{"key":"2023121405224366300_bib54","doi-asserted-by":"crossref","first-page":"e0263481","DOI":"10.1371\/journal.pone.0263481","article-title":"Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study","volume":"17","author":"Suhrs","year":"2022","journal-title":"PLoS One"},{"key":"2023121405224366300_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12933-022-01607-4","article-title":"Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report","volume":"21","author":"Leccisotti","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2023121405224366300_bib56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2023121405224366300_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2023121405224366300_bib58","doi-asserted-by":"crossref","first-page":"e015298","DOI":"10.1161\/CIRCIMAGING.123.015298","article-title":"Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023121405224366300_bib59","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14]","volume":"42","author":"Mcdonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023121405224366300_bib60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2023121405224366300_bib61","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.amjcard.2019.08.011","article-title":"Frequency of coronary microvascular dysfunction and diffuse myocardial fibrosis (Measured by Cardiovascular Magnetic Resonance) in patients with heart failure and preserved left ventricular ejection fraction","volume":"124","author":"L\u00f6ffler","year":"2019","journal-title":"Am J Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad053\/51176961\/pvad053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/741\/54021835\/pvad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/741\/54021835\/pvad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:23:27Z","timestamp":1702513407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/8\/741\/7232498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad053","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,7,27]]}}}